Cheniere Energy vs Vaxcyte Inc. Common Stock — how do they compare? Cheniere Energy trades at $280.95 (market cap $59.26B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Cheniere Energy is far larger — about 5.6× Vaxcyte Inc. Common Stock's market cap, and Cheniere Energy pays a 0.77% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 12 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| LNG | PCVX | |
|---|---|---|
Market Cap | $59.26B | $10.51B |
Volume | 1,056,751 | 2,644,694 |
Sector | Energy | Health |
52-Week High | $296.91 | $73.82 |
52-Week Low | $188.83 | $40.32 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $84.72B | $9.14B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Cheniere Energy (LNG) trades at $286.92, up 1.57% on the day, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a 45.23% ROE and 13.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights the company's long-term growth through a 22-year LNG supply deal with Petrobras, supporting its position in the energy sector.
The outlook is positive with a consensus price target of $307.44, representing 7.2% upside potential. Risks include earnings volatility and capital expenditure demands from growth projects. Analyst sentiment is overwhelmingly bullish with 92.59% buy ratings, but investors should monitor execution on expansion initiatives and energy market dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →